467 related articles for article (PubMed ID: 12019073)
21. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model.
Nicolau DP; Mattoes HM; Banevicius M; Xuan D; Nightingale CH
Antimicrob Agents Chemother; 2003 May; 47(5):1630-5. PubMed ID: 12709332
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
Crandon JL; Banevicius MA; Nicolau DP
Antimicrob Agents Chemother; 2009 Mar; 53(3):1165-9. PubMed ID: 19114676
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model.
Hegde SS; Okusanya OO; Skinner R; Shaw JP; Obedencio G; Ambrose PG; Blais J; Bhavnani SM
Antimicrob Agents Chemother; 2012 Mar; 56(3):1578-83. PubMed ID: 22155835
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.
Thabit AK; Crandon JL; Nicolau DP
Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208
[TBL] [Abstract][Full Text] [Related]
26. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.
Jones RN; Rubino CM; Bhavnani SM; Ambrose PG;
Antimicrob Agents Chemother; 2003 Jan; 47(1):292-6. PubMed ID: 12499204
[TBL] [Abstract][Full Text] [Related]
27. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
Madaras-Kelly KJ; Ostergaard BE; Hovde LB; Rotschafer JC
Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
[TBL] [Abstract][Full Text] [Related]
28. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint.
Drusano GL; Preston SL; Hardalo C; Hare R; Banfield C; Andes D; Vesga O; Craig WA
Antimicrob Agents Chemother; 2001 Jan; 45(1):13-22. PubMed ID: 11120938
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a neutropenic mouse thigh infection model.
Griffith DC; Rodriguez D; Corcoran E; Dudley MN
Antimicrob Agents Chemother; 2008 Jan; 52(1):244-7. PubMed ID: 17954697
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
[TBL] [Abstract][Full Text] [Related]
31.
Lepak AJ; Zhao M; VanScoy B; Taylor DS; Ellis-Grosse E; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396549
[TBL] [Abstract][Full Text] [Related]
32.
Zhao M; Lepak AJ; Marchillo K; VanHecker J; Andes DR
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416552
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model.
Xuan D; Banevicius M; Capitano B; Kim MK; Nightingale C; Nicolau D
Antimicrob Agents Chemother; 2002 Sep; 46(9):2990-5. PubMed ID: 12183258
[TBL] [Abstract][Full Text] [Related]
34. In vivo pharmacodynamics of new lipopeptide MX-2401.
Craig WA; Andes DR; Stamstad T
Antimicrob Agents Chemother; 2010 Dec; 54(12):5092-8. PubMed ID: 20855736
[TBL] [Abstract][Full Text] [Related]
35. In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.
Otsu Y; Yanagihara K; Fukuda Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
Antimicrob Agents Chemother; 2003 Dec; 47(12):3699-703. PubMed ID: 14638468
[TBL] [Abstract][Full Text] [Related]
36. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.
Firsov AA; Vostrov SN; Lubenko IY; Drlica K; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 2003 May; 47(5):1604-13. PubMed ID: 12709329
[TBL] [Abstract][Full Text] [Related]
37. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.
van Ogtrop ML; Andes D; Stamstad TJ; Conklin B; Weiss WJ; Craig WA; Vesga O
Antimicrob Agents Chemother; 2000 Apr; 44(4):943-9. PubMed ID: 10722495
[TBL] [Abstract][Full Text] [Related]
38. In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
Sugihara K; Sugihara C; Matsushita Y; Yamamura N; Uemori M; Tokumitsu A; Inoue H; Kakuta M; Namba E; Nasu H; Koga T
Antimicrob Agents Chemother; 2010 Dec; 54(12):5298-302. PubMed ID: 20921311
[TBL] [Abstract][Full Text] [Related]
39. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses.
Zinner SH; Firsov AA; Gilbert D; Simmons K; Lubenko IY
J Antimicrob Chemother; 2001 Dec; 48(6):821-6. PubMed ID: 11733466
[TBL] [Abstract][Full Text] [Related]
40.
Zhou YF; Tao MT; He YZ; Sun J; Liu YH; Liao XP
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
